Loading people...
Camille Samuels is a Partner at Venrock based in the San Francisco Bay Area, where she focuses on early-stage healthcare and biotechnology investments. Before joining the venture firm, she served as a Managing Director at Versant Ventures and worked in corporate development at Tularik. She holds a Master of Business Administration from Harvard Business School and a Bachelor of Arts in Biology from Duke University. Recognized as a multi-year honoree on the Forbes Midas List, she has spent over two decades backing life sciences companies through major initial public offerings and acquisitions. Her notable portfolio investments include early backing for RayzeBio, which was acquired by Bristol Myers Squibb for approximately $4.1 billion in February 2024, alongside Caribou Biosciences. Samuels currently dedicates her expertise to developing novel therapeutics by advising founders on scaling clinical-stage biopharmaceutical businesses.
Camille Samuels stands as a prominent Partner at Venrock, a venerable venture capital firm renowned for its early-stage investments in transformative technology and life sciences companies. Joining Venrock in 2011, Camille has carved out a significant niche, primarily focusing on pioneering opportunities within the healthcare and biotechnology sectors. Her investment philosophy centers on identifying and nurturing companies that are poised to revolutionize patient care and scientific discovery.
As a key investor at Venrock, Camille Samuels brings a wealth of experience and a keen eye for innovation to her role. She actively seeks out early-stage ventures developing novel therapeutics, advanced diagnostics, digital health platforms, and cutting-edge medical devices. Her commitment extends beyond capital, offering strategic guidance and operational support to founders as they navigate the complex landscape of product development, regulatory approvals, and market entry.
Camille's impressive career trajectory before Venrock provided her with a robust foundation for her current endeavors. She previously held a pivotal role in business development at Genentech, a leading biotechnology corporation, where she gained invaluable insights into the intricacies of drug discovery and commercialization. Prior to Genentech, Camille honed her strategic acumen as a consultant at McKinsey & Company, advising diverse clients on critical business challenges. This unique blend of scientific understanding, strategic consulting, and business development expertise makes her an exceptionally insightful and effective investor.
Throughout her tenure at Venrock, Camille Samuels has been instrumental in backing several highly successful companies that have gone on to make significant impacts. Among her notable investments are Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases; Unity Biotechnology, which develops therapeutics to slow, halt, or reverse diseases of aging; and Lyra Health, a leading provider of mental health benefits. These investments underscore her ability to identify companies with strong scientific foundations and significant market potential, ultimately driving innovation that improves human health. Founders seeking strategic partners in the healthcare and biotech space often look to Camille Samuels for her deep industry knowledge and proven track record.
Camille Samuels is a Partner at Venrock, a leading venture capital firm. She specializes in early-stage investments within the healthcare and biotechnology sectors, supporting innovative companies and founders.
Camille Samuels primarily invests in early-stage companies in healthcare and biotechnology. This includes areas like novel therapeutics, advanced diagnostics, digital health, and medical devices.
Camille Samuels works as a Partner at Venrock, a prominent venture capital firm with offices in various locations, including Palo Alto and New York.
